Fintel reports that on February 23, 2024, Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Overweight recommendation. Analyst Price Forecast Suggests 49.42% Upside.

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC) stock, maintaining a positive outlook on the company’s future.The research firm’s analyst ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued to investors ...

Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website highlighting data on mevrometostat data in ...

On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ: ORIC), maintaining an Overweight stock rating.Trading at $11.49, ORIC has seen analyst targets ranging from ...